JPRN-UMIN000015686Completed未知
A clinical multicenter study on efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism - A clinical multicenter study on efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism
Obstetrics and Gynecology, Hamamatsu University School of Medicine.0 sites30 target enrollmentStarted: November 13, 2014Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 16years-old to ot applicable (—)
- Sex
- Female
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with anaphylactic reaction to C1-inhibitor concentrate.
Investigators
Similar Trials
Completed
Phase 3
A Study to Evaluate Efficacy of DDX-01 which Supports Screening for Diabetic Retinopathy and Diabetic Macular EdemaDiabetisJPRN-jRCT2032220358Tomita Koji275
Active, not recruiting
Phase 1
A multicentre study to assess the safety and efficacy of sodium hyaluronate (Hyalgan-F) produced by fermentation in knee psteoarthritis.Knee oasteoarthritisEUCTR2005-002735-27-LVFidia Farmaceutici SpA120
Completed
Phase 2
A multicentre study to assess safety and efficacy of COMP360 in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU)treatment resistant depression10027946NL-OMON55052COMPASS Pathfinder Ltd3
Active, not recruiting
Phase 1
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873EUCTR2020-001348-25-CZCOMPASS Pathfinder, Ltd150
Active, not recruiting
Phase 1
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialEUCTR2020-001348-25-PTCOMPASS Pathways, Ltd150